“Are you at risk of developing a chronic disease? Trunome can help you catch it early!”
Trunome is a healthcare brand that offers advanced diagnostic testing and monitoring services for the early detection of chronic diseases such as diabetes, heart disease, and cancer.
Using state-of-the-art technology and highly trained medical professionals, Trunome ensures accurate and timely results so patients can begin treatment as soon as possible. By catching chronic diseases early, Trunome helps patients reduce the risk of complications and lead healthier lives.
Healthcare Business in India(Case study)
Trunome believes that prevention is better than cure and is committed to providing affordable, convenient, and accessible services to everyone, regardless of age or medical history. The brand is dedicated to providing personalized care and support to every patient.
Those interested in taking control of their health can schedule an appointment with Trunome or visit their website to learn more about their services and read testimonials from satisfied patients.
With Trunome, patients can trust that they will receive accurate and timely results, personalized care, and support to lead healthier and happier lives.
Entrepreneur Name – Agragesh Ramani and Avinash Ramani
About the Entrepreneur – The company was founded by Agragesh Ramani and Avinash Ramani, both of whom hail from Chennai.
Avinash, who holds a Ph.D. in molecular biology, comes from a clinical background with a strong scientific foundation.
LinkedIn Profile- https://www.linkedin.com/in/agrageshramani/?originalSubdomain=in
| Brand Name– | Trunome |
| Brand Website- | https://acrannolife.com/ |
| Business Category– | Health and Medical |
Innovation – Yes, With a goal of facilitating early detection of chronic illnesses, AcronLife Genomics is a clinical genomics enterprise that centers on technology-based solutions tailored to contemporary living.
The company strives to create a computational platform for the timely diagnosis of chronic ailments.
| Company Valuation– | ₹75 Crores. |
| Equity Asked– | ₹1.5 cr for 1% Equity |
| Deal Closed– | Yes. |
| Final Shark Tank Deal– | ₹1.5 cr for 2% Equity |
| Target City/Country- | India |
| Product/Services– | Early Diagnosis & Monitor Chronic Disease |
About the Product – In India, approximately 200,000 patients are afflicted with chronic diseases like organ transplants, and this figure rises by 40,000 each year.
The process of organ transplantation is in itself an agonizing and traumatic experience, and post-operative monitoring is expensive, hazardous, and painful.
To address these issues, the innovative technology Trunome was created. Trunome is a patented technology that enables the early detection and monitoring of chronic diseases, including cancer recurrence, via blood tests.
Notably, Trunome boasts a US-patent and CDSCO-approved facility, with a demonstrated accuracy rate of 100% in results.
To date, over 5,000 samples have been tested, and more than 1,500 lives impacted through partnerships with leading hospitals, including six in India.
The creators of Trunome envision positively affecting over a billion individuals with their technology, improving their quality of life, and ensuring their physical, mental, and emotional well-being.
Conclusion –
Agragesh Ramani and Avinash Ramani initially requested a sum of ₹1.5 crores for 1% equity. However, Shark Peyush countered with an offer of 1.5 crores for 2% equity.
Anupam offered 1.5 crores for 1.75% equity, while Veenita proposed 75 lakhs for 1% equity and 75 lakhs of interest-free debt.
Collectively, all four sharks offered 1.5 crores for 2% equity. The owners responded with a counteroffer of 3 crores for 2.5% equity.
Ultimately, the deal was finalized with Peyush, Anupam, Veenita, and Aman at 1.5 crores for 2% equity.
Trunome Shark Tank India Review